8-KAcquisitions & DispositionsExhibits & Filings

Merck & Co., Inc. 8-K Report, Acquisition Completed (Jun 3, 2021)

Filed June 3, 2021For Securities:MRK

Summary

Merck & Co., Inc. (MRK) announced the completion of the separation of its Organon & Co. business segment, which housed its women's health, biosimilars, and established brands divisions. This separation occurred on June 2, 2021, following a distribution of Organon common stock to Merck shareholders of record as of May 17, 2021. Each Merck shareholder received one-tenth of a share of Organon for every share of Merck they held, with cash provided for fractional shares. The company structured this distribution to be tax-free for its shareholders, with the exception of cash received for fractional shares, making this a significant strategic move for Merck to focus on its core growth areas.

Key Highlights

  • 1Merck completed the separation of its Organon & Co. business segment on June 2, 2021.
  • 2Organon encompasses Merck's former women's health, biosimilars, and established brands businesses.
  • 3A pro rata distribution of Organon common stock was made to Merck shareholders of record on May 17, 2021.
  • 4Shareholders received one-tenth of an Organon share for each Merck share held.
  • 5Cash will be provided in lieu of fractional Organon shares.
  • 6The distribution is designed to be tax-free for Merck shareholders, excluding cash for fractional shares.

Frequently Asked Questions

Organon & Co. consists of Merck's former women's health, biosimilars, and established brands businesses. The separation allows Merck to streamline its operations and focus on its key growth areas, particularly in innovative medicines and vaccines.

Merck shareholders of record on May 17, 2021, received one-tenth of a share of Organon common stock for every share of Merck common stock they owned. This was distributed on June 2, 2021.

Merck shareholders will receive cash in lieu of any fractional shares of Organon they would have been entitled to. This cash payment will be taxable, unlike the distribution of whole Organon shares.

The distribution of Organon shares is intended to be tax-free for Merck shareholders. However, any cash received in lieu of fractional shares will be considered taxable income.